Cordatus Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cordatus Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,044	Closed	-$584K	–	152
2020 Q3	$584K	Buy	1,044 +2	+0.2%	+$1.21K	0.28%	103
2020 Q2	$650K	Sell	1,042 -961	-48%	-$545K	0.36%	89
2020 Q1	$978K	Buy	+2,003	New	+$826K	0.7%	57
2019 Q2	–	Sell	-10,350	Closed	-$4.25M	–	137
2019 Q1	$4.25M	Buy	+10,350	New	+$4.26M	2.34%	7

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cordatus Wealth Management's REGN Position: Q4 2020 in Review

Cordatus Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 1,044 shares — an estimated $584K sold.

Cordatus Wealth Management first reported a position in REGN in Q1 2019 and held it in 4 quarters. The position peaked at $4.25M in Q1 2019. 903 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

Cordatus Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Cordatus Wealth Management sold 1,044 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $584K.
Cordatus Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 4 quarters.
Cordatus Wealth Management's Regeneron Pharmaceuticals position peaked at $4.25M in Q1 2019.
903 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Cordatus Wealth Management's 13F filing for Q4 2020, filed 2 Feb 2021.